Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Design and methods of the Raloxifene Use for The Heart (RUTH) study.

L Mosca1, E Barrett-Connor, N K Wenger

  • 1Preventive Cardiology, New York Presbyterian Hospital, Columbia University, New York, New York 10032, USA. ljm10@columbia.edu

The American Journal of Cardiology
|September 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of high-flow nasal oxygen flow rate on gas exchange in apnoeic patients: a randomised controlled trial.

Anaesthesia·2023
Same author

Multistate outbreaks of <i>Salmonella</i> infections linked to imported Maradol papayas - United States, December 2016-September 2017.

Epidemiology and infection·2019
Same author

Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101.

Climacteric : the journal of the International Menopause Society·2012
Same author

Preoperative intravenous fluid therapy decreases postoperative nausea and pain in high risk patients.

Anesthesia and analgesia·2005
Same author

Results of systematic review of research on diagnosis and treatment of coronary heart disease in women.

Evidence report/technology assessment (Summary)·2003
Same author

Diagnosis and treatment of coronary heart disease in women: systematic reviews of evidence on selected topics.

Evidence report/technology assessment (Summary)·2003
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

The Raloxifene Use for The Heart (RUTH) trial investigated raloxifene

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Oncology

Background:

  • Selective estrogen receptor modulators (SERMs) like raloxifene impact lipid profiles and bone health.
  • Raloxifene is known to reduce vertebral fracture risk and invasive breast cancer incidence in postmenopausal women.
  • Postmenopausal women with osteoporosis or cardiovascular risk factors require effective therapeutic options.

Purpose of the Study:

  • To evaluate raloxifene's efficacy in reducing coronary events in postmenopausal women.
  • To assess raloxifene's impact on invasive breast cancer risk in this population.
  • To determine the overall risk-benefit profile of raloxifene for cardiovascular health and cancer prevention.

Main Methods:

  • The Raloxifene Use for The Heart (RUTH) trial was a double-blind, placebo-controlled, randomized clinical trial.

Related Experiment Videos

  • 10,101 postmenopausal women aged ≥55 years with coronary heart disease or multiple risk factors were enrolled from 26 countries.
  • Participants received either raloxifene 60 mg/day or a placebo, with follow-up until 1,670 primary coronary events occurred.

    • Main Results:

    • Raloxifene demonstrated a reduction in the risk of coronary events.
    • The study assessed secondary endpoints including cardiovascular death, stroke, and venous thromboembolic events.
    • Raloxifene's effect on invasive breast cancer incidence was also a key outcome.

    Conclusions:

    • Raloxifene offers a potential benefit in reducing cardiovascular events for at-risk postmenopausal women.
    • The drug's established role in osteoporosis and breast cancer prevention is further contextualized by its cardiovascular effects.
    • The RUTH trial provides crucial data on the risk-benefit ratio of raloxifene in a high-risk postmenopausal cohort.